CHRISTOPHER MORACHE: Open Payments
NPI 1689621567 · SAN DIEGO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,657 in 72 payments from 14 companies in 2025. Trend: 2023 $1,117 · 2024 $2,187 · 2025 $1,657
Food & beverage: $1,657
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 12 | $404 |
| E.R. Squibb & Sons, L.L.C. | 12 | $256 |
| ABBVIE INC. | 9 | $160 |
| Supernus Pharmaceuticals, Inc. | 7 | $152 |
| Otsuka America Pharmaceutical, Inc. | 10 | $149 |
| Janssen Pharmaceuticals, Inc | 4 | $112 |
| Alkermes, Inc. | 4 | $83 |
| Vanda Pharmaceuticals Inc. | 3 | $82 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $70 |
| Almatica Pharma LLC | 3 | $63 |
Products named: INGREZZA, COBENFY, REXULTI, Qelbree, VRAYLAR, ARISTADA, FANAPT, SPRAVATO.
Industry payments across CA — which companies pay providers there.
